SEC EDGARJUN 22 min read$LGND

Reardon Andrew sold $133K of LGND

Reardon Andrew (CLO & Secretary) sold 584 shares of LIGAND PHARMACEUTICALS INC (LGND) at $228.57 ($0.13M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Reardon Andrew

Published Jun 2, 2026, 10:22 PM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Jun 2, 2026, 10:27 PM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

alphai market briefInsider activity

Primary signal

$LGND

Neutral

medium confidence

Mentioned

$LGND

Relevance

6/10

alphai data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$LGNDNeutralLow

Why it matters

The disclosure provides a datapoint on insider activity but does not, by itself, change fundamentals when pre-arranged.

Market read

Near-term trading impact is likely limited; any effect would be sentiment/positioning rather than new fundamentals.

What to watch

Traders may overreact to insider selling; the key is whether there are concurrent news catalysts (trial results, guidance, partnership updates) not present here.

Relevance 6/10Novelty 6/10Timing: Filed today; sale executed 2026-06-01.

Background

SEC Form 4 reports insider transactions; a 10b5-1 plan indicates trades were set in advance under SEC rules.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$LGNDNeutralMedium confidence

Context

Ligand Pharmaceuticals officer Andrew Reardon sold 584 shares in an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Small, short-lived sentiment impact possible; unlikely to drive a sustained move absent other catalysts.

Evidence & confidence

The filing is a routine insider transaction with explicit 10b5-1 pre-arrangement, reducing the probability it reflects new negative information.

Market effects

Sector

Minimal; this is company-specific insider activity with no stated operational/clinical/regulatory change.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

issuer
Ligand Pharmaceuticals Inc
Subject of the Form 4 insider sale by an officer under a 10b5-1 plan.
insider
Andrew Reardon
CLO & Secretary who sold 584 shares on 2026-06-01.

Read at source ← All news

SEP 4

$LGNDHighAI 8/10

Ligand Pharmaceuticals (LGND): Massive XOMA Acquisition Doubles The Royalty Book

Ligand Pharmaceuticals (LGND) reported Q2 2026 revenue of $63.7M, up 32% YoY, driven by royalty revenue growth. The company acquired XOMA Royalty, doubling its royalty portfolio and adding $700M in convertible debt. Ligand raised its full-year adjusted earnings guidance, but expenses increased due to the acquisition and other costs. The stock trades at a forward P/E of 25.19.

insidermonkey.com3 min

AUG 13

$LGNDHighAI 9/10

Ligand (LGND) Q2 2026 Earnings Call Transcript

Ligand Pharmaceuticals (LGND) reported Q2 2026 revenue of $63.7M, up 34%, driven by $48.0M royalty revenue (+32%). Adjusted diluted EPS was $2.37 (+48%). 2026 guidance raised to adjusted EPS $9.00-$9.50 and revenue $270M-$310M. Cash and short-term investments were $1.36B after a $700M convertible note. The XOMA Royalty acquisition added 120 assets.

fool.com6 min

AUG 8

$LGNDMed

Ligand Pharmaceuticals Incorporated Q2 2026 Earnings Call Summary

Ligand Pharmaceuticals reported Q2 2026 results and discussed its XOMA Royalty acquisition, adding 120+ assets and extending cash flow duration through 2040. Management cited 32% YoY royalty revenue growth and expects 2026 royalty revenue of $225M-$250M with cash opex halved since 2022. Ligand issued a $700M zero-coupon convertible, raised 2026 adjusted EPS guidance to $9.00-$9.50, and expects accretion from XOMA in 2H26 and 2027.

yahoo.com7 min

AUG 6

$LGNDMed

LIGAND PHARMACEUTICALS INC (LGND): Results of Operations and Financial Condition

LIGAND PHARMACEUTICALS INC (LGND) filed an SEC Form 8-K — Results of Operations and Financial Condition. Ligand Reports Second Quarter 2026 Financial Results Second quarter performance driven by strong year-over-year royalty revenue growth of 32% Raises Low End of 2026 Adjusted EPS Guidance; Revenue Guidance Unchanged Conference call begins at 8:30 a.m. Eastern Time today JUPITER, F

SEC EDGAR 8-K6 min

JUL 14

$LGNDMedAI 9/10

XOMA Royalty Announces Closing of Its Acquisition by Ligand

XOMA Royalty said Ligand Pharmaceuticals (Nasdaq: LGND) completed its acquisition of XOMA Royalty. Under the April 27 deal, XOMA shareholders received $39.00 cash per share and one non-transferable CVR per share tied to 75% of net proceeds from certain pending litigation. XOMA shares no longer trade on Nasdaq.

manilatimes.net2 min